+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 173 Pages
  • February 2024
  • Region: Global
  • Grand View Research
  • ID: 5893261
Description Jump to:
The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments.Such advancements collectively aim to achieve a higher yield of quality products.

Recombinant Protein Therapeutics CDMO Market Report Highlights

  • The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases
  • Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications
  • Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field
  • North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. InternalL Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details Of Primary Research
1.4. Information Or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4
Chapter 2. Chapter 2 Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.1.1. Rising Adoption Of Biologics And Biosimilars
3.2.1.2. Technological Innovations About The Development Of Novel Recombinant Protein Therapeutics
3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Hurdles
3.2.2.2. Challenges Related To Quality Control
3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
3.5. Covid-19 Impact On Bioprocessing And Outsourcing
3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
3.5.2. Supply Chain
3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
3.5.4. Changes In The Long Term
Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Growth Hormones
4.1.2. Interferons
4.1.3. Vaccines
4.1.4. Immunostimulating Agents
4.1.5. Others
4.2. Segment Dashboard
4.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
4.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4.1. Growth Hormones
4.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.2. Interferons
4.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.3. Vaccines
4.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.4. Immunostimulating Agents
4.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.5. Others
4.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Mammalian Systems
5.1.2. Microbial Systems
5.1.3. Others
5.2. Segment Dashboard
5.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
5.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
5.4.1. Mammalian Systems
5.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
5.4.2. Microbial Systems
5.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
5.4.3. Others
5.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Oncology
6.1.2. Infectious Diseases
6.1.3. Immunological Disorders
6.1.4. Metabolic Disorders
6.1.5. Haematological Disorders
6.1.6. Others
6.2. Segment Dashboard
6.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
6.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4.1. Oncology
6.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.2. Infectious Diseases
6.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.3. Immunological Disorders
6.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.4. Metabolic Disorders
6.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.5. Haematological Disorders
6.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.7. South Korea
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2023
8.3. Major Deals and Strategic Alliances Analysis
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Richter-Helm BioLogics
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Lonza
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Catalent, Inc
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. FUJIFILM Diosynth Biotechnologies
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. WuXi Biologics
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Curia Global, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Batavia Biosciences B.V.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. HALIX B.V.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BIOVIAN
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Enzene Biosciences Ltd
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 4 North America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 5 North America Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 6 U.S. Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 9 Canada Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 10 Canada Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 11 Canada Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 12 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 13 Europe Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 14 Europe Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 15 Europe Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 16 UK Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 17 UK Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 18 UK Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 19 Germany Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 20 Germany Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 21 Germany Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 22 France Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 23 France Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 24 France Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 25 Italy Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 26 Italy Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 27 Italy Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 28 Spain Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 29 Spain Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 30 Spain Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 31 Denmark Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 34 Sweden Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 37 Norway Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 38 Norway Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 39 Norway Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 44 Japan Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 45 Japan Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 46 Japan Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 47 China Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 48 China Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 49 China Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 50 India Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 51 India Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 52 India Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 53 Australia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 54 Australia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 55 Australia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 56 Thailand Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 57 Thailand Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 58 Thailand Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 60 South Korea Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 61 South Korea Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 62 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 65 Brazil Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 66 Brazil Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 68 Mexico Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 69 Mexico Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 71 Argentina Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 72 Argentina Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 74 MEA Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 75 MEA Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 76 MEA Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 77 MEA Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 78 South Africa Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 79 South Africa Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 84 UAE Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 85 UAE Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 86 UAE Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 87 Kuwait Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 88 Kuwait Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Recombinant protein therapeutics CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2022 (USD Billion)
Fig. 16 Ancillary market outlook, 2022 (USD Billion)
Fig. 17 Recombinant protein therapeutics CDMO market dynamics
Fig. 18 Porter’s five forces analysis
Fig. 19 PESTEL analysis
Fig. 20 Recombinant protein therapeutics CDMO market type outlook: Segment dashboard
Fig. 21 Recombinant protein therapeutics CDMO market, by type segment: Market share, 2023 & 2030
Fig. 22 Growth hormones market, 2018 - 2030 (USD Million)
Fig. 23 Interferons market, 2018 - 2030 (USD Million)
Fig. 24 Vaccines market, 2018 - 2030 (USD Million)
Fig. 25 Immunostimulating agents market, 2018 - 2030 (USD Million)
Fig. 26 Others market, 2018 - 2030 (USD Million)
Fig. 27 Recombinant protein therapeutics CDMO market source outlook: Segment dashboard
Fig. 28 Recombinant protein therapeutics CDMO market, by source segment: Market share, 2023 & 2030
Fig. 29 Mammalian systems market, 2018 - 2030 (USD Million)
Fig. 30 Microbial systems market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 Recombinant protein therapeutics CDMO market indication outlook: Segment dashboard
Fig. 33 Recombinant protein therapeutics CDMO market, by indication segment: Market share, 2023 & 2030
Fig. 34 Oncology market, 2018 - 2030 (USD Million)
Fig. 35 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 36 Immunological disorders market, 2018 - 2030 (USD Million)
Fig. 37 Metabolic disorders market, 2018 - 2030 (USD Million)
Fig. 38 Haematological disorders market, 2018 - 2030 (USD Million)
Fig. 39 Others market, 2018 - 2030 (USD Million)
Fig. 40 Regional market: Key takeaways
Fig. 41 Regional marketplace: Key takeaways
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 U.S. recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Canada recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 48 Europe recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 49 Key country dynamics
Fig. 50 UK recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Germany recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 France recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Italy recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Spain recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Sweden recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Denmark recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Norway recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 65 Asia Pacific recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Japan recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 China recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 India recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 Australia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Clinical trial approval process in South Korea
Fig. 76 South Korea recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Thailand recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 79 Latin America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Brazil recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Mexico recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Argentina recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 86 MEA recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 South Africa recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 Saudi Arabia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Clinical trial authorization process UAE
Fig. 93 UAE recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Kuwait recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 96 Market participant categorization
Fig. 97 Market participant categorization
Fig. 98 Heat map analysis

Companies Mentioned

  • Richter-Helm BioLogics
  • Lonza
  • Catalent, Inc
  • FUJIFILM Diosynth Biotechnologies
  • WuXi Biologics
  • Curia Global, Inc.
  • Batavia Biosciences B.V.
  • HALIX B.V.
  • BIOVIAN
  • Enzene Biosciences Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages173
PublishedFebruary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 20.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 52 Billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Upstream, Downstream), By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Upstream, Downstream), By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Healthcare CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Healthcare CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 150 Pages
  • Global
From
CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 319 Pages
  • Global
Biologics CDMO Global Market Report 2024 - Product Image

Biologics CDMO Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the Market

Recombinant Protein Therapeutics CDMO (Contract Development and Manufacturing Organization) is a specialized service provider that assists in the development and manufacturing of recombinant proteins for drug discovery. These proteins are produced through recombinant DNA technology, which involves the insertion of a gene into a host organism to produce a desired protein. CDMOs provide a range of services, including process development, analytical testing, and manufacturing of recombinant proteins. They also provide support for regulatory compliance and quality assurance. Recombinant protein therapeutics are used in drug discovery to identify and develop new treatments for diseases. They are also used to develop biologics, which are drugs derived from living organisms. The use of recombinant proteins in drug discovery has enabled the development of treatments for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. Companies in the Recombinant Protein Therapeutics CDMO market include Lonza, Boehringer Ingelheim, Merck KGaA, and Fujifilm Diosynth Biotechnologies. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.